Evidence map›Paper›PMID 35802311›Full record

ArticleAngiogenesis2022

Therapeutic angiogenesis for patients with no-option critical limb ischemia by adipose-derived regenerative cells: TACT-ADRC multicenter trial.

Yuuki Shimizu, Kazuhisa Kondo, Ryo Hayashida, Ken-Ichiro Sasaki, Masanori Ohtsuka, Yoshihiro Fukumoto, Shinichiro Takashima, Oto Inoue, Soichiro Usui, Masayuki Takamura and 12 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Angiogenesis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 1 country.

Yuuki ShimizuDepartment of Cardiology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, 466-8550, Japan. shimi123@med.nagoya-u.ac.jp.ORCID 0000-0003-3103-1160
Kazuhisa KondoDepartment of Cardiology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, 466-8550, Japan.
Ryo HayashidaDepartment of Cardiology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, 466-8550, Japan.
Ken-Ichiro SasakiDivision of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.
Masanori OhtsukaDivision of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.
Yoshihiro FukumotoDivision of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan.
Shinichiro TakashimaDepartment of Cardiovascular Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
Oto InoueDepartment of Cardiovascular Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
Soichiro UsuiDepartment of Cardiovascular Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
Masayuki TakamuraDepartment of Cardiovascular Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
Masashi SakumaDepartment of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Japan.
Teruo InoueNasu Red Cross Hospital, Dokkyo Medical University, Otawara, Japan.
Tokuichiro NagataDepartment of Cardiovascular Surgery, St. Marianna University School of Medicine, Kawasaki City, Kanagawa, Japan.
Yoshihiro J AkashiDivision of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki City, Kanagawa, Japan.
Yoshihiro YamadaDepartment of Cardiovascular Medicine, Fukuoka Tokushukai Medical Center, Fukuoka, Japan.
Tamon KatoDepartment of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Koichiro KuwaharaDepartment of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Kaoru TatenoDepartment of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Yoshio KobayashiDepartment of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Rei ShibataDepartment of Advanced Cardiovascular Therapeutics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Toyoaki MuroharaDepartment of Cardiology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, 466-8550, Japan. murohara@med.nagoya-u.ac.jp.
TACT-ADRC multicenter trial Group
Kanazawa University · JPNagoya University · JPKurume University · JPChiba University · JPDokkyo Medical University · JPShinshu University · JPSt. Marianna University School of Medicine · JPFukuoka Tokushukai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with critical limb ischemia (CLI) still have a high rate of lower limb amputation, which is associated with not only a decrease in quality of life but also poor life prognosis. Implantation of adipose-derived regenerative cells (ADRCs) has an angiogenic potential for patients with limb ischemia.

objectivesWe investigated safety, feasibility, and efficacy of therapeutic angiogenesis by cell transplantation (TACT) of ADRCs for those patients in multicenter clinical trial in Japan.

methodsThe TACT-ADRC multicenter trial is a prospective, interventional, open-labeled study. Patients with CLI (Fontaine class III-IV) who have no other option for standard revascularization therapy were enrolled in this study. Thirty-four target ischemic limbs of 29 patients were received freshly isolated autologous ADRCs implantation.

resultsThe overall survival rate at a post-operative period and at 6 months follow-up was 100% at any time points. As a primary endpoint for efficacy evaluation, 32 limbs out of 34 (94.1%) were free from major amputation for 6 months. Numerical rating scale (from 6 to 1) as QOL score, ulcer size (from 317 mm

conclusionsImplantation of autologous ADRCs could be safe and effective for the achievement of therapeutic angiogenesis in the multicenter settings, as a result in no major adverse event, optimal survival rate, and limb salvage for patients with no-conventional option against critical limb ischemia. TRN: jRCTb040190118; Date: Nov. 24th, 2015.

Indexed as

Chronic Limb-Threatening IschemiaQuality of LifeAmputation, SurgicalHumansIschemiaNeovascularization, PathologicProspective StudiesTreatment OutcomeAdipose-derived regenerative cellsCritical limb ischemiaMulticenter clinical trialTherapeutic angiogenesis

Identifiers

PMID35802311
PMCPMC9263817
OpenAlexW4284894692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.